Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
Over the past years, a series of recalls have been triggered globally by cancer-causing impurities detected in popular medicines. Among them is metformin, and the latest research shows that a carcinogen found in the diabetes drug was likely produced when…
To read the full story
Related Article
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- Towa Launches Task Force to Tackle Nitrosamine Impurities, Share Solutions with Peers
July 24, 2025
- Towa Develops Analytical Method for Nitrosamine in Antidepressant Duloxetine
March 12, 2024
- Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
- Towa, Nichi-Iko Recalling Some Metformin Products over Carcinogen Risks, Follow 2 Makers
September 17, 2020
- Sumitomo Dainippon, Nihon Generic Pulling Some Metformin Products over Carcinogen Risks
April 28, 2020
- Metformin Manufacturers Ordered to Test for Potential Carcinogen Contamination
December 10, 2019
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…